86. 肺動脈性肺高血圧症 Pulmonary arterial hypertension Clinical trials / Disease details

臨床試験数 : 1,205 / 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193

20 trials found

diseases per page:

Showing 1 to 10 of 20 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03833323 (ClinicalTrials.gov)	August 1, 2020	5/2/2019	Implantable System for Remodulin Post-Approval Study	Implantable System for Remodulin Post-Approval Study	Pulmonary Arterial Hypertension	Combination Product: Implantable System for Remodulin (treprostinil)	Medtronic Cardiac Rhythm and Heart Failure	United Therapeutics	Withdrawn	22 Years	N/A	All	0		NULL
2	NCT04309838 (ClinicalTrials.gov)	March 2020	20/2/2020	Observation Study With Implantable Medication Pump for Intravenous Treprostinil Therapy in Patients ...	LENUS Pro® Study (LPS-II) - Observation Study With Implantable Medication Pump for Intravenous REMOD ...	Pulmonary Arterial Hypertension;PAH	Combination Product: Treprostinil via implanted pump	University Medicine Greifswald	OMT GmbH & Co. KG	Not yet recruiting	18 Years	N/A	All	30		Germany
3	NCT02882126 (ClinicalTrials.gov)	June 2017	24/8/2016	An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® ...	An Open-Label Extension Trial to Evaluate the Safety of Continued Therapy With Subcutaneous Remoduli ...	Pulmonary Arterial Hypertension	Drug: Subcutaneous Treprostinil	United Therapeutics	CVie Therapeutics Co. Ltd.	Withdrawn	18 Years	N/A	All	0	Phase 4	China
4	NCT03016468 (ClinicalTrials.gov)	May 2017	6/1/2017	Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH	A Multicenter, 16-Week, Open-label Study Evaluating the Safety of Transition From Selexipag to Remod ...	Pulmonary Arterial Hypertension	Drug: Parenteral Remodulin (treprostinil) injection;Drug: Oral Treprostinil	United Therapeutics	NULL	Withdrawn	18 Years	75 Years	All	0	Phase 2	NULL
5	NCT02893995 (ClinicalTrials.gov)	February 2017	24/8/2016	Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® ...	A 16-Week, Open-Label, Multi-Center, Parallel, Randomized Controlled Study to Compare the Safety, To ...	Pulmonary Arterial Hypertension	Drug: Slow Dose Titration Group of Subcutaneous Treprostinil;Drug: Rapid Dose Titration Group of Sub ...	United Therapeutics	CVie Therapeutics Co. Ltd.	Withdrawn	18 Years	N/A	All	0	Phase 4	China
6	NCT02276872 (ClinicalTrials.gov)	December 18, 2014	21/10/2014	Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to ...	A Multicenter, Open-Label, 24-Week, Uncontrolled Study to Evaluate the Safety, Tolerability, and Pha ...	PAH	Drug: oral treprostinil	United Therapeutics	NULL	Completed	7 Years	17 Years	All	32	Phase 2	United States
7	NCT02847260 (ClinicalTrials.gov)	April 2012	25/7/2016	Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects ( ...	A 16 Week, Open Label, Multi-centre, Study to Evaluate the Safety, Tolerability and Pharmacodynamic ...	Pulmonary Arterial Hypertension	Drug: Remodulin	United Therapeutics	NULL	Completed	18 Years	N/A	All	39	Phase 4	NULL
8	NCT01588405 (ClinicalTrials.gov)	April 2012	6/1/2012	Remodulin® to Oral Treprostinil Transition	A Multicenter, Open-Label Study of the Safety and Tolerability of Transitioning From Remodulin® to O ...	Pulmonary Arterial Hypertension	Drug: UT-15C SR	United Therapeutics	NULL	Completed	15 Years	80 Years	All	33	Phase 2	United States
9	EUCTR2011-004631-31-DE (EUCTR)	13/03/2012	10/02/2012	16 week study is to assess the safety, tolerability and the effects on the body of a rapid dosing re ...	A 16 Week, Open Label, Multi-Centre, Study to Evaluate the Safety, Tolerability and Pharmacodynamic ...	Pulmonary Arterial Hypertension (PAH) MedDRA version: 14.1;Level: PT;Classification code 10064911;Te ...	Trade Name: Remodulin® (treprostinil) 1 mg/ml solution for infusion INN or Proposed INN: Treprostinil ...	United Therapeutics Corp.	NULL	Not Recruiting			Female: yes Male: yes	50		Germany
10	NCT01393795 (ClinicalTrials.gov)	August 2011	22/6/2011	Qutenza®-Remodulin® in Pulmonary Arterial Hypertension Patients	A Double-blind, Randomized, Crossover Clinical Study to Assess the Efficacy of Qutenza® for the Redu ...	Pulmonary Hypertension;Pain	Drug: Qutenza;Drug: Tegaderm	Imperial College London	United Therapeutics	Completed	18 Years	N/A	Both	11	Phase 2	United Kingdom

First Previous1 2Next Last